Ad-hoc | 24 October 2002 07:31

MorphoSys AG english

MorphoSys Announces Share Issuance for XOMA License Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Announces Share Issuance for XOMA License MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, today announced that the Management Board has resolved to issue 303,466 shares to XOMA after a capital increase against contribution in kind, subject to registration in the commercial register. As a contribution, XOMA granted a license to MorphoSys as part of a transaction announced earlier this year. The share capital was raised under exclusion from preemptive rights under the Company’s articles of association. The shares issued to XOMA represent approx. 7.7 % of the outstanding share capital of MorphoSys AG. In February 2002, MorphoSys and XOMA signed a cross-license agreement for their antibody-related technologies. MorphoSys and its partners received a license from XOMA to use XOMA’s antibody expression technology for the development and production of antibody products using MorphoSys’ phage display-based HuCAL antibody library. XOMA receives a license to use the MorphoSys HuCAL GOLD library and, among other financial terms, a one-time license payment from MorphoSys. The share issuance announced today represents full and complete satisfaction of the outstanding obligations under said transaction. end of ad-hoc-announcement (c)DGAP 24.10.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 240731 Okt 02